← Eichor
Condition: Metastatic Non Small Cell Lung Cancer With Mtap Deletion Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Non Small Cell Lung Cancer With Mtap Deletion

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus
Phase 2/Phase 3 · 318 location(s) · Bristol-Myers Squibb · NCT07063745Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Phase 1/Phase 2 · 18 location(s) · Tango Therapeutics, Inc. · NCT06922591A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Phase 1 · 16 location(s) · IDEAYA Biosciences · NCT07277413A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer
Phase 2 · 70 location(s) · Bristol-Myers Squibb · NCT06855771
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.